BHST

Company Overview — What Does BIOHARVEST SCIENCES INC. Do?

BioHarvest Sciences Inc. operates as a biotechnology company. The company operates through Nutraceuticals and Pharmaceuticals segments. It develops botanical synthesis platform technology to grow the ingredients in any plant enzymes or cells. The company is leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions in nutraceuticals and pharmaceuticals verticals. It also operates as a contract development and manufacturing operation services. In addition, the company offers wellness products. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red grapes. The company operates in Israel and the United States. BioHarvest Sciences Inc. is based in Vancouver, Canada. BIOHARVEST SCIENCES INC. (BHST) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Ilan Sobel. With a market capitalization of $98M, BHST is one of the notable companies in the Healthcare sector.

BIOHARVEST SCIENCES INC. (BHST) Stock Rating — Reduce (April 2026)

As of April 2026, BIOHARVEST SCIENCES INC. receives a Reduce rating with a composite score of 37.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.BHST ranks #2,745 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, BIOHARVEST SCIENCES INC. ranks #374 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

BHST Stock Price and 52-Week Range

BIOHARVEST SCIENCES INC. (BHST) currently trades at $4.31. The stock gained $0.03 (0.7%) in the most recent trading session. The 52-week high for BHST is $12.80, which means the stock is currently trading -66.3% from its annual peak. The 52-week low is $4.10, putting the stock 5.1% above its annual trough. Recent trading volume was 18K shares, suggesting relatively thin trading activity.

Is BHST Overvalued or Undervalued? — Valuation Analysis

BIOHARVEST SCIENCES INC. (BHST) carries a value factor score of 26/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 73.45x, versus the sector average of 2.75x. The price-to-sales ratio is 0.97x, compared to 1.66x for the average Healthcare stock.

At current multiples, BIOHARVEST SCIENCES INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

BIOHARVEST SCIENCES INC. Profitability — ROE, Margins, and Quality Score

BIOHARVEST SCIENCES INC. (BHST) earns a quality factor score of 41/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -3883.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -206.6% versus the sector average of -33.1%.

On a margin basis, BIOHARVEST SCIENCES INC. reports gross margins of 55.4%, compared to 71.5% for the sector. The operating margin is -27.8% (sector: -66.1%). Net profit margin stands at -51.3%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

BHST Debt, Balance Sheet, and Financial Health

BIOHARVEST SCIENCES INC. has a debt-to-equity ratio of 294.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. Total debt on the balance sheet is $4M. Cash and equivalents stand at $2M.

BHST has a beta of 0.80, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for BIOHARVEST SCIENCES INC. is 37/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

BIOHARVEST SCIENCES INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, BIOHARVEST SCIENCES INC. reported revenue of $25M and earnings per share (EPS) of $-0.80. Net income for the quarter was $-13M. Gross margin was 55.4%. Operating income came in at $-7M.

In FY 2024, BIOHARVEST SCIENCES INC. reported revenue of $25M and earnings per share (EPS) of $-0.80. Net income for the quarter was $-13M. Gross margin was 55.4%. Revenue grew 98.8% year-over-year compared to FY 2023. Operating income came in at $-7M.

In FY 2023, BIOHARVEST SCIENCES INC. reported revenue of $13M and earnings per share (EPS) of $-0.93. Net income for the quarter was $-13M. Gross margin was 44.5%. Operating income came in at $-10M.

BHST Dividend Yield and Income Analysis

BIOHARVEST SCIENCES INC. (BHST) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

BHST Momentum and Technical Analysis Profile

BIOHARVEST SCIENCES INC. (BHST) has a momentum factor score of 36/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 18/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 64/100 reflects moderate short selling activity.

BHST vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, BIOHARVEST SCIENCES INC. (BHST) ranks #374 out of 838 stocks based on the Blank Capital composite score. This places BHST in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing BHST against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BHST vs S&P 500 (SPY) comparison to assess how BIOHARVEST SCIENCES INC. stacks up against the broader market across all factor dimensions.

BHST Next Earnings Date

No upcoming earnings date has been announced for BIOHARVEST SCIENCES INC. (BHST) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy BHST? — Investment Thesis Summary

The quantitative profile for BIOHARVEST SCIENCES INC. suggests caution. The value score of 26/100 indicates premium valuation. Momentum is weak at 36/100, a headwind for near-term performance. High volatility (stability score 37/100) increases portfolio risk.

In summary, BIOHARVEST SCIENCES INC. (BHST) earns a Reduce rating with a composite score of 37.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BHST stock.

Related Resources for BHST Investors

Explore more research and tools: BHST vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BHST head-to-head with peers: BHST vs AZN, BHST vs SLGL, BHST vs VMD.